Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

NCT02156466 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: MSB0010841
DRUG: MSB0010841
DRUG: MSB0010841
DRUG: MSB0010841
DRUG: Placebo

Sponsor

Merck KGaA, Darmstadt, Germany